Bruker (NASDAQ:BRKR) issued its earnings results on Thursday. The medical research company reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.02, Bloomberg Earnings reports. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The firm had revenue of $530.50 million for the quarter, compared to analyst estimates of $506.74 million. During the same period in the previous year, the company posted $0.46 earnings per share. The business’s revenue was up 12.8% on a year-over-year basis. Bruker updated its FY18 guidance to $1.34 to $1.38 EPS.
Bruker (BRKR) traded down $1.54 during trading on Thursday, reaching $31.62. The company had a trading volume of 1,040,000 shares, compared to its average volume of 484,321. Bruker has a twelve month low of $21.83 and a twelve month high of $36.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. The stock has a market capitalization of $4,920.00, a PE ratio of 33.64, a price-to-earnings-growth ratio of 2.50 and a beta of 1.05.
A number of research firms recently issued reports on BRKR. BTIG Research began coverage on Bruker in a research note on Friday, January 5th. They set a “buy” rating and a $42.00 price objective on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a research note on Thursday, December 14th. Zacks Investment Research upgraded Bruker from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research note on Thursday, January 4th. BidaskClub lowered Bruker from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Evercore ISI began coverage on Bruker in a research note on Wednesday, January 3rd. They set an “in-line” rating and a $36.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company’s stock. Bruker currently has a consensus rating of “Hold” and an average price target of $32.38.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.